Silence Therapeutics plc is a London-based, clinical-stage biotechnology company focused on RNAi therapeutics, using short interfering RNA (siRNA) to silence disease-associated genes.[1] The company’s current visual identity dates to May 2007, when it was introduced alongside a corporate name change from SR Pharma plc.
Design and History
The Silence Therapeutics identity was created as part of a broader rebranding effort announced in 2007. On 26 April 2007, shareholders approved changing the company’s name from SR Pharma plc to Silence Therapeutics plc, a change that took effect on 30 April 2007.[2] The company stated that the new name and corporate identity were put in place “to better reflect the Company’s core focus on RNAi, a therapeutic approach which seeks to ‘silence’ disease relevant genes.”[3]
The rebranding was accompanied by a new website, which went live on 2 May 2007.[2] The company’s interim report for 2007 noted that the decision to rename the group was “designed to further enhance our profile in the RNAi space.”[4]
Meaning and Symbolism
The name “Silence Therapeutics” directly references the company’s scientific approach. RNAi therapeutics work by “silencing” disease-relevant genes, a concept that is central to both the company’s name and its stated mission of “silencing diseases through precision engineered medicines.”[1][3]
Typography and Design
No official documentation has been located that identifies the specific designer, agency, or typeface used in the Silence Therapeutics logo. The current mark is available in both full and icon formats, including versions designed for use on dark backgrounds.[5] The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007.[5]
Logo Index is an independent educational archive covering logos, visual identities and graphic design history. All trademarks and brand assets remain the property of their respective owners.
